Notice: This company has been marked as potentially delisted and may not be actively trading. Acasti Pharma (ACST) Insider Trading & Ownership Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrends Acasti Pharma (NASDAQ:ACST) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage13.51%Number OfInsiders Buying(Last 3 Years)2Amount OfInsider Buying(Last 3 Years)$1.25 MNumber OfInsiders Selling(Last 3 Years)0 Get ACST Insider Trade Alerts Want to know when executives and insiders are buying or selling Acasti Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ACST Insider Buying and Selling by Quarter Remove Ads Acasti Pharma Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/25/2023Vimal KavuruDirectorBuy676,371$1.85$1,251,286.35 8/31/2023Donald OldsDirectorBuy381$2.05$781.05 (Data available from 1/1/2013 forward) ACST Insider Trading Activity - Frequently Asked Questions Who is on Acasti Pharma's Insider Roster? The list of insiders at Acasti Pharma includes Donald Olds, and Vimal Kavuru. Learn more on insiders at ACST. What percentage of Acasti Pharma stock is owned by insiders? 13.51% of Acasti Pharma stock is owned by insiders. Learn more on ACST's insider holdings. Which Acasti Pharma insiders have been buying company stock? The following insiders have purchased ACST shares in the last 24 months: Donald Olds ($781.05), and Vimal Kavuru ($1,251,286.35). How much insider buying is happening at Acasti Pharma? Insiders have purchased a total of 676,752 ACST shares in the last 24 months for a total of $1,252,067.40 bought. Acasti Pharma Key ExecutivesMr. Prashant Kohli (Age 52)CEO & Director Compensation: $358.41kMr. Robert J. DelAversano CPA (Age 52)Principal Financial & Accounting Officer Dr. R. Loch MacDonald M.D. (Age 62)Ph.D., Member of Scientific Advisory Board & Chief Medical Officer Mr. Amresh Kumar Ph.D. (Age 44)VP of Program Management Ms. Carrie D'Andrea (Age 52)VP of Clinical Operations More Insider Trading Tools from MarketBeat Related Companies Seres Therapeutics Insider Transactions Coherus BioSciences Insider Transactions Adaptimmune Therapeutics Insider Transactions Sutro Biopharma Insider Transactions Invivyd Insider Transactions Coya Therapeutics Insider Transactions Kyverna Therapeutics Insider Transactions Sagimet Biosciences Insider Transactions Fate Therapeutics Insider Transactions Vaxart Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Companies Buying Back Stock—Why It MattersInsider Scoop: 4 Stocks Insiders Are Buying and Selling2 Stocks Insiders Are Buying and 1 They're Selling3 Stocks With Robust Growth Outlooks Insiders Are BuyingMETA Stock: Insider Selling Ramps Up—What It Means for Investors This page (NASDAQ:ACST) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for March 13th. Because on that day, I believe we could see a $2 Trillion shock INTO the...Timothy Sykes | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredWarning: What they're not telling you about these recent selloffsIn light of massive recent selloffs... our senior analyst Dan Ferris has issued a new warning for the American...Stansberry Research | SponsoredSilent Raid on IRAs and 401(k)s Begins—Are You Next?Look around—everything feels oddly steady. Gas prices aren't skyrocketing. Banks aren't collapsing. The mar...Genesis Gold Group | SponsoredTrump announces revenge on BidenA former CIA insider just made a stunning prediction: Trump’s revenge on Biden will end America’s energy cr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acasti Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acasti Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
